TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
22.52 ^USD	+5.88%		+13.11%	+31.85%

17/06	Declaration of Voting Results by TG Therapeutics	CI
17/06	Declaration of Voting Results by TG Therapeutics	CI

TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2018

January 24, 2018 at 06:00 pm IST

TG Therapeutics, Inc. announced that updated data for ublituximab (TG-1101), the company’s novel glycoengineered anti-CD20 monoclonal antibody, has been selected for presentation at the upcoming third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018, to be held February 1 - 3, 2018, in San Diego, California.

Latest news about TG Therapeutics, Inc.

Declaration of Voting Results by TG Therapeutics	18/06	CI
Declaration of Voting Results by TG Therapeutics	18/06	CI
Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission	13/06	CI
Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM	11/06
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics	10/06	CI
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05	MT
Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	01/05
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	01/05	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
North American Morning Briefing : Investors Brace -2-	29/04	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Sector Update: Health Care	19/04	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04	CI
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	14/03	MT
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01/03	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	29/02	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	29/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	26/02	MT

Chart TG Therapeutics, Inc.

Duration

Period

More charts

Company Profile

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for TG Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.52 USD

Average target price

31.5 USD

Spread / Average Target

+39.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TG THERAPEUTICS, INC.	+31.85%	3.22B
MODERNA, INC.	+25.83%	47.96B
IQVIA HOLDINGS INC.	+0.69%	42.45B
LONZA GROUP AG	+44.64%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research